TY - JOUR
T1 - Development of the lichen planus quality of life questionnaire (LPQoL) informed by expert clinician input and patient feedback
T2 - a retrospective survey study
AU - The Mayo Clinic Lichen Planus Consortium
AU - Xie, Fangyi
AU - Morken, Colleen M.
AU - Zhang, Nan
AU - Pittelkow, Mark R.
AU - Sartori Valinotti, Julio C.
AU - Comfere, Nneka I.
AU - Meves, Alexander
AU - Murphree, Dennis H.
AU - Mangold, Aaron R.
AU - Lehman, Julia S.
N1 - Funding Information:
Dr Xie is funded by the British Association of Dermatologist's Geoffrey Dowling Fellowship for her visiting research fellowship. The research is funded from the Appignani Lichen Planus Benefactor Gift. The funders have not been involved in the review process.
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2023
Y1 - 2023
N2 - Lichen planus (LP) can affect multiple body sites including skin, mucosae, scalp and nails, causing considerable impact on patients’ quality of life. Currently, there are no LP patient-reported outcome measures (PROMs) that address all body sites potentially affected by LP. We developed a LP Quality of Life Questionnaire (LPQoL), informed by an expert consortium and patient survey study, to address this gap. The study was approved by our institution’s Institutional Review Board. First, a 22-item LPQoL was designed with input from LP experts at our institution. The tool was then optimized by garnering input from patients recently diagnosed with LP, who were asked to complete the LPQoL, as well as the Dermatology Life Quality Index (DLQI) and a feedback form about the LPQoL. Fifty-eight of 150 patients (39% response rate) returned the questionnaire. Mean DLQI score was 4.9 ± 5.6 SD (range 0–25) and mean LPQoL score was 13.6 ± 10.4 SD (range 0–54). LPQoL score was positively correlated with DLQI score (r = 0.79; p < 0.001). Forty-nine out of 56 (88%) and 6/56 (11%) rated the LPQoL as ‘very easy’ or ‘fairly easy’ to complete, respectively. Based on participants’ feedback, we increased the recall period from one week to one month and added questions on esophageal involvement. With iterative input from LP experts and patients, we developed a LPQoL to address the gap in a multi-site PROM specific to LP. This is a pilot study and there is ongoing validation studies; therefore, this measure should not be used in clinical practice or research until validated.
AB - Lichen planus (LP) can affect multiple body sites including skin, mucosae, scalp and nails, causing considerable impact on patients’ quality of life. Currently, there are no LP patient-reported outcome measures (PROMs) that address all body sites potentially affected by LP. We developed a LP Quality of Life Questionnaire (LPQoL), informed by an expert consortium and patient survey study, to address this gap. The study was approved by our institution’s Institutional Review Board. First, a 22-item LPQoL was designed with input from LP experts at our institution. The tool was then optimized by garnering input from patients recently diagnosed with LP, who were asked to complete the LPQoL, as well as the Dermatology Life Quality Index (DLQI) and a feedback form about the LPQoL. Fifty-eight of 150 patients (39% response rate) returned the questionnaire. Mean DLQI score was 4.9 ± 5.6 SD (range 0–25) and mean LPQoL score was 13.6 ± 10.4 SD (range 0–54). LPQoL score was positively correlated with DLQI score (r = 0.79; p < 0.001). Forty-nine out of 56 (88%) and 6/56 (11%) rated the LPQoL as ‘very easy’ or ‘fairly easy’ to complete, respectively. Based on participants’ feedback, we increased the recall period from one week to one month and added questions on esophageal involvement. With iterative input from LP experts and patients, we developed a LPQoL to address the gap in a multi-site PROM specific to LP. This is a pilot study and there is ongoing validation studies; therefore, this measure should not be used in clinical practice or research until validated.
KW - Lichen planopilaris
KW - Lichen planus
KW - Mucosal disease
KW - Patient-reported outcome measures
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=85147016725&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147016725&partnerID=8YFLogxK
U2 - 10.1007/s00403-023-02534-4
DO - 10.1007/s00403-023-02534-4
M3 - Article
AN - SCOPUS:85147016725
SN - 0340-3696
JO - Archives of Dermatological Research
JF - Archives of Dermatological Research
ER -